دورية أكاديمية
Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer.
| العنوان: | Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer. |
|---|---|
| المؤلفون: | Jiménez-Fonseca P; Medical Oncology Department, Asturias Central University Hospital, Carretera de Rubín s/n Finca 'La Cadellada', 33011, Oviedo, Asturias, Spain, palucaji@hotmail.com., Solis MP, Garrido M, Faez L, Rodriguez D, Ruiz AL, Sanchez Lorenzo ML, Uriol E, Menendez MD, Viéitez JM |
| المصدر: | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2015 May; Vol. 17 (5), pp. 384-92. Date of Electronic Publication: 2014 Nov 27. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2010- >: Milan : Springer Italia Original Publication: Barcelona, Spain : Doyma, c2005- |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Bone Neoplasms/*drug therapy , Colonic Neoplasms/*pathology , Liver Neoplasms/*drug therapy , Lung Neoplasms/*drug therapy , Peritoneal Neoplasms/*drug therapy , Rectal Neoplasms/*pathology, Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bone Neoplasms/secondary ; Capecitabine/administration & dosage ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Disease-Free Survival ; Female ; Humans ; Liver Neoplasms/secondary ; Lung Neoplasms/secondary ; Lymphatic Metastasis ; Male ; Middle Aged ; Peritoneal Neoplasms/secondary ; Retreatment ; Retrospective Studies ; Survival Rate ; Gemcitabine |
| مستخلص: | Purpose: A proportion of patients with metastatic colorectal cancer (mCRC) are still able to continue with active therapy after their progression to fluoropyrimidines, oxaliplatin, and irinotecan regimens. Studies suggest that gemcitabine and fluoropyrimidines are synergic antimetabolites. The purpose was to evaluate gemcitabine-capecitabine (Gem-Cape) in heavily pretreated mCRC and to thus assess possible predictive factors for progression-free survival (PFS) and overall survival (OS). Patients and Methods: This analysis was performed on 119 evaluable patients pretreated with fluoropyrimidines, oxaliplatin, irinotecan, and biological agents between June 2001 and July 2011. Patients received gemcitabine 1,000 mg/m(2) day 1 and capecitabine 1,000 mg/m(2) bid for 7 days every 2 weeks. Results: The general characteristics were ECOG 0-1, 89 %; male, 68 %, and median age 63 years. In total, 61 % had received two chemotherapy lines, while 39 % had received three or more. Objective response rates and stable disease rates at 3 months were 6.72 and 37.81 %, equalling a clinical benefit of 44.53 %. The median PFS and OS were 2.87 months [95 % confidence interval (CI) 2.53-3.17 months] and 6.53 months (95 % CI 5.33-8.77), respectively. The most frequent toxicities were grades 1-2, anemia (22 %), thrombocytopenia (10 %), and hand-foot syndrome (9 %); grade ≥3, diarrhea (2 %), with no treatment-related discontinuations. No treatment-related deaths were reported. Statistical significance was obtained by subgroups, assessing clinical benefits and objective responses for PFS and OS. Moreover, patients under 65 tended to have a better PFS. Conclusion: These data suggest that Gem-Cape is a tolerable and feasible regimen, associated with clinical benefit in non-selected, heavily pretreated, mCRC patients. |
| التعليقات: | Erratum in: Clin Transl Oncol. 2015 May;17(5):416-7. (PMID: 25480119) |
| References: | Oncologist. 2010;15(1):73-84. (PMID: 20067946) Cancer Res Treat. 2012 Jun;44(2):127-32. (PMID: 22802751) Lancet. 2013 Jan 26;381(9863):303-12. (PMID: 23177514) Cancer Res. 1991 Nov 15;51(22):6110-7. (PMID: 1718594) Anticancer Res. 2008 Sep-Oct;28(5B):3055-60. (PMID: 19031956) Lancet Oncol. 2013 Jan;14(1):29-37. (PMID: 23168366) Oncology (Williston Park). 2000 Sep;14(9):1297-306; discussion 1309-11. (PMID: 11033828) Mol Pharmacol. 1990 Oct;38(4):567-72. (PMID: 2233693) J Clin Oncol. 2002 Jan 15;20(2):582-7. (PMID: 11786589) J Clin Oncol. 2004 Oct 1;22(19):3950-7. (PMID: 15459217) J Clin Oncol. 2000 Oct 15;18(20):3553-7. (PMID: 11032598) Expert Opin Investig Drugs. 2009 Sep;18(9):1257-64. (PMID: 19678797) Clin Cancer Res. 1998 Nov;4(11):2811-8. (PMID: 9829747) J Clin Oncol. 2007 May 1;25(13):1658-64. (PMID: 17470858) World J Gastroenterol. 2012 Jan 7;18(1):25-33. (PMID: 22228967) |
| المشرفين على المادة: | 0W860991D6 (Deoxycytidine) 6804DJ8Z9U (Capecitabine) 0 (Gemcitabine) |
| تواريخ الأحداث: | Date Created: 20141128 Date Completed: 20160219 Latest Revision: 20221207 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC4544491 |
| DOI: | 10.1007/s12094-014-1243-1 |
| PMID: | 25428757 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1699-3055 |
|---|---|
| DOI: | 10.1007/s12094-014-1243-1 |